Please use this identifier to cite or link to this item:
Title: Characterisation of the immune evasion phenotype of Richter Syndrome and the implications for immune checkpoint therapy.
Epworth Authors: Yannakou, Costas
Other Authors: Gould, Clare
Lickiss, Jennifer
Kankanige, Yamuna
Yerneni, Satwica
Markham, John
Villa, Diego
Slack, Graham
Chin, Collin
Tam, Constantine
Lade, Stephen
Nelson, Niles
Neeson, Paul
Seymour, John
Dickinson, Michael
Westerman, David
Blombery, Piers
Keywords: Immune Evasion Phenotype
Richter Syndrome
Immune-Checkpoint Inhibitor Therapy
Chronic Lymphocytic Leukemia
High-Grade B-Cell Lymphoma
Anti-PD-1 Monotherapy
Genetic Biomarkers
Immune-Checkpoint Molecules
Immunohistochemical (IHC)
De novo (Non-Transformed) DLBCL
NK- Cell Markers
T- Cell Markers
CTLA4 Gene Expression
Malignant B-Cells (CD19)
Hybridization-Based NGS
Small Phase Two Trials
Cancer Services Clinical Institute, Epworth HealthCare, Victoria, Australia
Epworth Centre for Immunotherapies and Snowdome Laboratories
Department of Molecular Oncology and Cancer Immunology, Epworth HealthCare, East Melbourne, Victoria
Issue Date: Aug-2019
Citation: Blood (2019) 134 (Supplement_1): 4290
Conference Name: 61st American Society of Hematology (ASH 2019)
Conference Location: Orange County Convention Center (OCCC), Orlando, FL, USA
Abstract: Richter syndrome (RS) is the transformation of chronic lymphocytic leukemia (CLL) to a high-grade B-cell lymphoma and is associated with an aggressive clinical course and poor prognosis. Conventional treatment options for RS are generally associated with low response rates and limited durability making this entity an area of significant unmet therapeutic need. Immune checkpoint inhibitor therapy has shown promise in the treatment of some aggressive lymphoma subtypes. In RS, modest benefits have been reported in small phase two trials of anti-PD-1 monotherapy and in combination with ibrutinib, however larger scale studies are lacking (Ding et al Blood, 2017; Jain et al Blood, 2016). We sought to characterise the immune-evasion phenotype of RS focussing on potential genetic biomarkers which may inform the selection of patients who are most likely to benefit from immune-directed therapies.
DOI: 10.1182/blood-2019-127800
Type: Conference Poster
Affiliated Organisations: Cancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Australia
Molecular Haematology Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia
Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
British Columbia Cancer Centre for Lymphoid Cancer and Division of Medical Oncology, University of British Columbia, Vancouver, Canada
Centre for Lymphoid Cancer, BC Cancer, Vancouver, Canada
Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia
Royal Melbourne Hospital, Melbourne, Australia
St Vincent's Hospital, Melbourne, Australia
Type of Clinical Study or Trial: Clinical Trial
Appears in Collections:Cancer Services

Files in This Item:
There are no files associated with this item.

Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.